Impaired glucagon secretion in patients with fulminant type 1 diabetes mellitus.
Fulminant
Glucagon
Japanese
Type 1 diabetes
Journal
Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
19
06
2018
accepted:
04
09
2018
pubmed:
12
9
2018
medline:
28
4
2020
entrez:
12
9
2018
Statut:
ppublish
Résumé
Fulminant type 1 diabetes mellitus (FT1DM), characterized by rapid and almost complete destruction of pancreatic β-cells, is a newly identified subtype of type 1 diabetes mellitus. Although, the pathophysiology of this condition remains still unclear, histological evidence suggests that not only β-cells but also α-cells of pancreatic islets are reduced in number in FT1DM. However, the ability of glucagon secretion in patients with this condition has remained largely uncharacterized. We therefore examined glucagon secretion in patients with FT1DM and compared that with patients with other types of diabetes mellitus. Fasting glucagon levels as well as glucagon secretion induced by intravenous administration of arginine were measured in hospitalized 83 patients with diabetes mellitus, including 4 with FT1DM, 18 with type 1 diabetes mellitus (T1DM), 40 with type 2 diabetes mellitus (T2DM), 5 with slowly progressive insulin-dependent diabetes mellitus (SPIDDM), and 16 with pancreatic diabetes mellitus (PDM). The area under the curve for serum glucagon levels after arginine infusion in FT1DM patients was significantly smaller than that in T1DM, T2DM, or SPIDDM patients but was similar to that in PDM patients. The fasting serum glucagon level of FT1DM patients was lower than that of T1DM or T2DM patients but did not significantly differ from that of SPIDDM or PDM patients. These results suggest that glucagon secretion is impaired in patients with FT1DM.
Identifiants
pubmed: 30203124
doi: 10.1007/s12020-018-1750-x
pii: 10.1007/s12020-018-1750-x
doi:
Substances chimiques
Glucagon
9007-92-5
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
476-479Références
A. Imagawa, T. Hanafusa, J. Miyagawa, Y. Matsuzawa, A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. Osaka IDDM Study Group. N. Engl. J. Med. 342, 301–307 (2000)
doi: 10.1056/NEJM200002033420501
pubmed: 10655528
T. Hanafusa, A. Imagawa, Fulminant type 1 diabetes: a novel clinical entity requiring special attention by all medical practitioners. Nat. Clin. Pract. Endocrinol. Metab. 3, 36–45 (2007)
doi: 10.1038/ncpendmet0351
pubmed: 17179928
L. Liu, L. Zeng, D. Sang, Z. Lu, J. Shen, Recent findings on fulminant type 1 diabetes. Diabetes Metab. Res. Rev. 34(1), e2928 (2018)
doi: 10.1002/dmrr.2928
C. Moreau, D. Drui, G. Arnault-Ouary, B. Charbonnel, L. Chaillous, B. Cariou, Fulminant type 1 diabetes in Caucasians: a report of three cases. Diabetes Metab. 34, 529–532 (2008)
doi: 10.1016/j.diabet.2008.05.003
pubmed: 18829363
R.A. McCauley, X. Wang, Fulminant type 1 diabetes mellitus-like presentation in a Hispanic woman in the United States. Diabetes Metab. 37, 356–358 (2011)
doi: 10.1016/j.diabet.2011.04.005
pubmed: 21684789
M. Taniyama, R. Katsumata, K. Aoki, S. Suzuki, A Filipino patient with fulminant type 1 diabetes. Diabetes Care 27, 842–843 (2004)
doi: 10.2337/diacare.27.3.842
pubmed: 14988318
F. Tan, W.K. Loh, Fulminant type 1 diabetes associated with pregnancy: a report of 2 cases from Malaysia. Diabetes Res. Clin. Pract. 90, e30–e32 (2010)
doi: 10.1016/j.diabres.2010.08.009
pubmed: 20832134
A. Imagawa, T. Hanafusa, Y. Uchigata, A. Kanatsuka, E. Kawasaki, T. Kobayashi et al. Fulminant type 1 diabetes: a nationwide survey in Japan. Diabetes Care 26, 2345–2352 (2003)
doi: 10.2337/diacare.26.8.2345
pubmed: 12882860
Y.M. Cho, J.T. Kim, K.S. Ko, B.K. Koo, S.W. Yang, M.H. Park, et al. Fulminant type 1 diabetes in Korea: high prevalence among patients with adult-onset type 1 diabetes. Diabetologia 50, 2276–2279 (2007)
doi: 10.1007/s00125-007-0812-z
pubmed: 17724575
K. Sayama, A. Imagawa, K. Okita, S. Uno, M. Moriwaki, J. Kozawa et al. Pancreatic beta and alpha cells are both decreased in patients with fulminant type 1 diabetes: a morphometrical assessment. Diabetologia 48, 1560–1564 (2005)
doi: 10.1007/s00125-005-1829-9
pubmed: 15991022
S. Shibasaki, A. Imagawa, S. Tauriainen, M. Iino, M. Oikarinen, H. Abiru et al. Expression of toll-like receptors in the pancreas of recent-onset fulminant type 1 diabetes. Endocr. J. 57, 211–219 (2010)
doi: 10.1507/endocrj.K09E-291
pubmed: 20009359
D. D’Alessio, The role of dysregulated glucagon secretion in type 2 diabetes. Diabetes Obes. Metab. 13(Suppl 1), 126–132 (2011)
R.H. Unger, A.D. Cherrington, Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J. Clin. Invest. 122, 4–12 (2012)
doi: 10.1172/JCI60016
pubmed: 22214853
pmcid: 3248306
A. Imagawa, T. Hanafusa, T. Awata, H. Ikegami, Y. Uchigata, H. Osawa et al. Report of the Committee of the Japan Diabetes Society on the research of fulminant and acute-onset type 1 diabetes mellitus: new diagnostic criteria of fulminant type 1 diabetes mellitus. J. Diabetes Investig. 3, 536–539 (2012)
doi: 10.1111/jdi.12024
pubmed: 24843620
pmcid: 4015434
T. Kobayashi, S. Tanaka, N. Harii, K. Aida, H. Shimura, M. Ohmori et al.Immunopathological and genetic features in slowly progressive insulin-dependent diabetes mellitus and latent autoimmune diabetes in adults. Ann. NY Acad. Sci. 1079, 60–66 (2006)
doi: 10.1196/annals.1375.009
pubmed: 17130533
R.H. Unger, E. Aguilar-Parada, W.A. Müller, A.M. Eisentraut, Studies of pancreatic alpha cell function in normal and diabetic subjects. J. Clin. Invest. 49, 837–848 (1970)
doi: 10.1172/JCI106297
pubmed: 4986215
pmcid: 322540
R.H. Unger, L. Orci, Physiology and pathophysiology of glucagon. Physiol. Rev. 56, 778–826 (1976)
doi: 10.1152/physrev.1976.56.4.778
pubmed: 185634
D. Yabe, A. Kuroe, M. Ohya, K. Watanabe, N. Kitatani, M. Oku et al.A case of fulminant type 1 diabetes mellitus with exocrine pancreatic insufficiency and enhanced glucagon response to meal ingestion. Diabetes Res. Clin. Pract. 82, e1–e4 (2008)
doi: 10.1016/j.diabres.2008.08.004
pubmed: 18789550
T. Katsura, D. Kawamori, E. Aida, T.A. Matsuoka, I. Shimomura, Glucotoxicity induces abnormal glucagon secretion through impaired insulin signaling in InR1G cells. PLoS ONE 12, e0176271 (2017)
doi: 10.1371/journal.pone.0176271
pubmed: 28426798
pmcid: 5398759
W. Ogawa, K. Sakaguchi, Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors. J. Diabetes Investig. 7, 135–138 (2016)
doi: 10.1111/jdi.12401
pubmed: 27042263
A.K. Foulis, J.A. Stewart, The pancreas in recent-onset type 1 (insulin-dependent) diabetes mellitus: insulin content of islets, insulitis and associated changes in the exocrine acinar tissue. Diabetologia 26, 456–461 (1984)
doi: 10.1007/BF00262221
pubmed: 6381192
T. Hanafusa, A. Imagawa, Insulitis in human type 1 diabetes. Ann. NY Acad. Sci. 1150, 297–299 (2008)
doi: 10.1196/annals.1447.052
pubmed: 19120316
Y. Cui, D.K. Andersen, Pancreatogenic diabetes: special considerations for management. Pancreatology 11, 279–294 (2011)
doi: 10.1159/000329188
pubmed: 21757968
S. Shibasaki, A. Imagawa, J. Terasaki, T. Hanafusa, Endogenous insulin secretion even at a very low level contributes to the stability of blood glucose control in fulminant type 1 diabetes. J. Diabetes Investig. 1, 283–285 (2010)
doi: 10.1111/j.2040-1124.2010.00059.x
pubmed: 24843445
pmcid: 4014893